CDH3 and neoplasm: Alternatively, issues specific to solid tumors might limit antitumor activity; these issues include inherent tumor heterogeneity related to P-cadherin expression, as well as immunosuppressive stromal cells and the tumor microenvironment blunting an adequate CD8+ T-cell response (22).